Sean Fenske, Editor-in-Chief02.19.21
Ranfac Corp. has teamed with Endocellutions LLC to establish a joint venture that will seek to leverage the strengths of the two firms. Cervos Medical will offer a complete line of surgical and orthobiologic devices to address a number of needs, primarily within the orthopedic space.
The company will be the exclusive supplier of all co-developed products produced by Ranfac and Endocellutions. The Cervos portfolio will include bone marrow aspiration devices based on the Marrow Cellution technology. In addition, offered will be a family of minimally invasive bone harvesting devices, sub-chondral access tools, CELLFuse synthetic graft material, adipose processing systems, and a Platelet Rich Plasma (PRP) system.
“I am extremely excited to announce the formation of Cervos Medical,” announced Harlan Adler, CEO of Ranfac. “We have partnered with the Endo team for over 5 years and believe this to be an important next step as we continue to bring next generation devices to the marketplace. The proven advantages of the Marrow Cellution technology with its elimination of the need for centrifugation, along with its demonstrated higher quality biologic is especially important with the focus on disease transmission and infection in the age of COVID. Our on-going product development pipelines are robust and we believe the future of Cervos is very bright.”
Besides the orthopedic marketplace, the company’s product line will provide new solutions for sports medicine, trauma, spine, pain management, and aesthetics. The goal of Cervos is to work closely with the distribution and provider community to promote, train, and support these cutting-edge products in the marketplace.
“Endocellutions is very excited to be partnering with Ranfac in this new venture,” said Andrew McGillicuddy, CEO of Endocellutions. “Ranfac is a best-in-class medical device manufacturer with a long and successful operating history. Our next generation product offerings built on our cutting-edge technology will improve outcomes, save O.R. time, and reduce procedure costs. Cervos will focus on ongoing customer education and peer-to-peer engagement to share best practices and work closely with the distribution community. We have put together a great team in a very dynamic space and I am very excited and proud to be a part of it.”
The company will be the exclusive supplier of all co-developed products produced by Ranfac and Endocellutions. The Cervos portfolio will include bone marrow aspiration devices based on the Marrow Cellution technology. In addition, offered will be a family of minimally invasive bone harvesting devices, sub-chondral access tools, CELLFuse synthetic graft material, adipose processing systems, and a Platelet Rich Plasma (PRP) system.
“I am extremely excited to announce the formation of Cervos Medical,” announced Harlan Adler, CEO of Ranfac. “We have partnered with the Endo team for over 5 years and believe this to be an important next step as we continue to bring next generation devices to the marketplace. The proven advantages of the Marrow Cellution technology with its elimination of the need for centrifugation, along with its demonstrated higher quality biologic is especially important with the focus on disease transmission and infection in the age of COVID. Our on-going product development pipelines are robust and we believe the future of Cervos is very bright.”
Besides the orthopedic marketplace, the company’s product line will provide new solutions for sports medicine, trauma, spine, pain management, and aesthetics. The goal of Cervos is to work closely with the distribution and provider community to promote, train, and support these cutting-edge products in the marketplace.
“Endocellutions is very excited to be partnering with Ranfac in this new venture,” said Andrew McGillicuddy, CEO of Endocellutions. “Ranfac is a best-in-class medical device manufacturer with a long and successful operating history. Our next generation product offerings built on our cutting-edge technology will improve outcomes, save O.R. time, and reduce procedure costs. Cervos will focus on ongoing customer education and peer-to-peer engagement to share best practices and work closely with the distribution community. We have put together a great team in a very dynamic space and I am very excited and proud to be a part of it.”
